Please login to the form below

Not currently logged in

Lucid’s “spellbinding” performance prompts multiple wins at Communiqué 2018

Its haul included the Communications Consultancy of the Year

Lucid Group were in high spirits at last night’s Communiqué Awards - which celebrates exceptional healthcare communications work - after they were named the Communications Consultancy of the year.

Arguably the most coveted prize of the evening, The Communications Consultancy award is presented to those who demonstrated excellence in creative communications campaigns for clients coupled with evidence of a growing business.

The award’s judging panel, who was “spellbound” by the group’s performance this year, identified this excellence in Lucid, and said: “Lucid showed a sustained growth of 30% in a year that also saw a 46% surge in headcount and introduced flexible working.”

For this particular award, the group beat off competition from rivals 90TEN, Aurora, Incisive Health and Pegasus, the latter of which was recognised as a highly commended contender, an accolade awarded to those who missed out on first place by a hair’s breadth.

Lucid was equally as buoyant after receiving the award for Medical Education Consultancy of the Year, an award which encouraged any consultancy or agency to enter whose primary focus is medical education.

The judges for this category, who saw Lucid present their achievements earlier this year, said the group “demonstrated the authenticity of their patient centric approach showing a true focus on patient outcomes”.

They were also impressed with Lucid’s investment in their team and said Lucid’s “verve and decision making” has enabled “the company goals and aspirations to become a reality”.

Complete Medical Communications and Synergy Vision was recognised as finalists in this category while science communications group Oxford PharmaGenesis was awarded with the highly commended certificate.

Held at London’s Grosvenor House Hotel, the Communiqué Awards also saw Lucid work its magic in two other categories, one of which was The Porterhouse Medical Group Award for Excellence in Professional Education Programmes for its two-year hidradenitis suppurativa (HS) campaign for AbbVie.

Meanwhile, Lucid’s work in multiple sclerosis (MS) for Sanofi Genzyme triggered another win for the group in the Excellence in Communications via Meetings category.

Lucid, which was established 11 years ago, was shortlisted in five categories this year, and out of those the group took home four awards.

Jan Steele, chief operating officer and co-founder of Lucid, said: “We are thrilled for our teams and clients that their hard work and dedication to delivering transformative programmes has been recognised.

"We know that we are lucky to work with clients who share the same ambitions as us and who partner with us to deliver these pioneering programmes that change behaviour and ultimately improve patient outcomes.”

Run by PMLiVE's publisher the PMGroup, the Communiqué Awards recognise and reward outstanding work in healthcare communications across local, European and international markets.

* See all the 2018 Communiqué Awards results

Article by
Gemma Jones

25th June 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...